The world of catheter innovation has already seen remarkable strides this year— with some of the most promising medtech delivered into the body via catheter-based procedures. Think of improved ablation for treating AFib, coronary intravascular lithotripsy to combat coronary artery disease, and more. Here, we've highlighted the top five … [Read more...] about The top catheter innovation news stories of 2023 — so far
penumbra
How Penumbra’s smart-sucking algorithms and catheters speed up clot removal
Blood loss is a big problem when using aspiration catheters to remove blood clots from patients' veins and arteries. "You suck out the clot, you also suck out the blood," said Sandra Lesenfants, president of the interventional business at Penumbra (NYSE:PEN). Algorithms developed by Penumbra's software team for the company's continuous … [Read more...] about How Penumbra’s smart-sucking algorithms and catheters speed up clot removal
FDA clears Lightning Flash thrombectomy system from Penumbra
Penumbra (NYSE:PEN) announced today that it received FDA clearance for the Lightning Flash mechanical thrombectomy system. Alameda, California-based Penumbra also initiated the launch for the system. The company called Lightning Flash "the most advanced and powerful mechanical thrombectomy system on the market." Lightning Flash features the … [Read more...] about FDA clears Lightning Flash thrombectomy system from Penumbra
Penumbra launches RED reperfusion catheters in Europe
Penumbra (NYSE:PEN) announced today that it received the CE mark for its Penumbra RED reperfusion catheter and began the European launch. Alameda, California-based Penumbra designed its RED reperfusion catheter for the removal of all clot types in acute ischemic stroke (AIS) patients. The catheters are part of the Penumbra System — a fully … [Read more...] about Penumbra launches RED reperfusion catheters in Europe
Data backs Penumbra’s catheters for stroke care
Penumbra (NYSE:PEN) announced today that initial data support the use of its RED reperfusion catheters and the Penumbra System. Alameda, California-based Penumbra presented results from the initial Insight Registry for the RED reperfusion catheters and the sub-analyses of the Complete study for the Penumbra system at the 2022 World Federation of … [Read more...] about Data backs Penumbra’s catheters for stroke care
Penumbra grows sales 20% in Q1
Penumbra (NYSE:PEN) this week posted first-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Alameda, California-based company reported profits of $79,000, or -1¢ per share, on sales of $203.9 million for the three months ended March 31, for a sales growth of 20.5% compared with Q1 … [Read more...] about Penumbra grows sales 20% in Q1
Penumbra posts mixed-bag Q4 results, grows sales 22%
Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates. The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 … [Read more...] about Penumbra posts mixed-bag Q4 results, grows sales 22%
Data shows safety and strong performance for Penumbra’s Indigo CAT RX catheter
Penumbra (NYSE:PEN) announced today that the Cheetah clinical study for its Indigo CAT RX catheter met its primary endpoint. Alameda, California-based Penumbra’s Indigo catheter system demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in … [Read more...] about Data shows safety and strong performance for Penumbra’s Indigo CAT RX catheter
Penumbra beats the Street in Q3, grows sales 25%
Penumbra (NYSE:PEN) posted third-quarter results this week that beat the overall consensus on Wall Street. The Alameda, California-based company reported profits of $8.85 million, or 24¢ per share, on sales of $190.1 million for the three months ended Sept. 30, for a sales growth of 25.84% compared with Q3 2020. Adjusted to exclude one-time … [Read more...] about Penumbra beats the Street in Q3, grows sales 25%
Penumbra sales grow 75% in Street-beating Q2 results
Penumbra (NYSE:PEN) posted second-quarter results this week that beat the overall consensus on Wall Street. The Alameda, Calif.-based vascular conditions device company reported profits of $9.2 million, or 25¢ per share, on sales of $184.3 million for the three months ended June 30, for a sales growth of 75.3% compared with Q2 2020. Adjusted … [Read more...] about Penumbra sales grow 75% in Street-beating Q2 results
